Cadila scouts partners to ramp up Covid vaccine production by 50 to 70 mn

Cadila Healthcare Ltd., one of two Indian drugmakers racing to develop an indigenous Covid-19 vaccine, is in talks with potential partners to ramp up production capacity if its candidate passes human clinical trials.

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine, on top of the 100 million that will come from its own capacity, according to Managing Director Sharvil Patel. He declined to name the companies and the amount Cadila has invested in developing the vaccine.

“We’re just waiting for phase II to push that